BlossomHill Therapeutics Falls Post-$150M IPO in Cautious Biotech Debut
BlossomHill Therapeutics' post-IPO decline highlights investor caution toward cancer drugmakers, with the $150 million debut faltering on U.S. exchanges as biotech sentiment…
BlossomHill Therapeutics' post-IPO decline highlights investor caution toward cancer drugmakers, with the $150 million debut faltering on U.S. exchanges as biotech sentiment…
Technology stocks tumbled sharply on Wednesday, dragging down global equity benchmarks, while government bonds sold off and yields rose, reflecting a widespread…
ASX 200 nears a decade low as surging costs force profit downgrades across Australian equities, rattling investor sentiment.